8-K: Nukkleus Stockholders Approve Key Strategic Acquisitions & Capital Raises

Nukkleus Inc. stockholders overwhelmingly approved four critical proposals, including a strategic acquisition and multiple capital-raising initiatives, at a special meeting on December 16, 2025.

Summary

• Stockholders of Nukkleus Inc. held a special meeting on December 16, 2025, with a quorum of approximately 44.60% of outstanding shares (7,425,406 shares out of 16,645,766 outstanding).
• Proposal No. 1, the Star Purchase Proposal, was approved with 99.68% of votes cast, authorizing the acquisition of 100% of Star Capital 26, Inc. for a combination of cash and Company securities. This transaction involves Menachem Shalom, the CEO and a director of Nukkleus, who is also the CEO, a director, and controlling shareholder of Star.
• Proposal No. 2, the Warrant Shares Proposal, was approved with 99.19% of votes cast, allowing the issuance of 3,191,400 shares of Common Stock upon the exercise of restricted common stock purchase warrants at an exercise price of $5.405 per share.
• Proposal No. 3, the ELOC Issuance Proposal, was approved with 99.41% of votes cast, enabling the Company to sell up to $250,000,000 of Common Stock to Esousa Group Holdings, LLC.
• Proposal No. 4, the Preferred Stock Conversion Issuance Proposal, was approved with 99.40% of votes cast, facilitating the conversion of Series A Convertible Preferred Stock and exercise of warrants from a $10,000,000 investment by two institutional investors. The Series A Preferred Stock is initially convertible into 2,044,800 shares at an initial conversion price of $4.89 per share, subject to anti-dilution adjustments.

Sentiment

Score: 7

Explanation: The overwhelming approval of all proposals indicates strong shareholder support for the company's strategic direction, including an acquisition and significant capital raises. While dilution is a concern, the ability to secure funding and pursue growth initiatives is generally positive. The related party transaction introduces a minor governance concern, but the overall sentiment is positive due to successful execution of key corporate actions.

Positives

• Overwhelming stockholder approval for all proposals (each passed with over 99% of votes cast) indicates strong investor confidence in management's strategic direction.
• Approval of the Star Capital 26, Inc. acquisition suggests potential for business expansion and synergy within the company's operations.
• Authorization for significant capital raises, including up to $250,000,000 from Esousa Group Holdings, LLC and $10,000,000 from institutional investors, provides substantial financial flexibility and strengthens the balance sheet.
• The ability to issue shares upon warrant exercise and preferred stock conversion allows the company to fulfill existing obligations and potentially bring in additional capital.

Negatives

• The acquisition of Star Capital 26, Inc. involves a related party transaction, with Menachem Shalom serving as CEO and director for both Nukkleus and Star, which could raise corporate governance concerns regarding potential conflicts of interest.
• The various share issuances (for the Star acquisition, warrants, ELOC, and preferred stock conversion) will lead to significant dilution for existing shareholders, as several proposals involve issuing shares in excess of 19.99% or 20% of outstanding common stock.
• The Series A Preferred Stock conversion price is subject to price-based anti-dilution adjustments, which could lead to further dilution if the stock price declines.

Risks

• Dilution Risk: The issuance of a substantial number of new shares for the Star acquisition, warrant exercises, ELOC agreement, and preferred stock conversion will dilute the ownership percentage of current stockholders.
• Related Party Transaction Risk: The acquisition of Star Capital 26, Inc. from a controlling shareholder who is also the CEO and a director of Nukkleus Inc. presents a potential conflict of interest, which could lead to scrutiny or perceived unfair terms.
• Market Price Volatility Risk: The conversion price of Series A Preferred Stock is subject to adjustment based on the trading price of the Common Stock, which could lead to more shares being issued if the stock price falls, exacerbating dilution.
• Integration Risk: The acquisition of Star Capital 26, Inc. carries inherent risks related to integrating the acquired business, including operational, financial, and cultural challenges.

Future Outlook

The approval of these proposals indicates the company's intent to proceed with the acquisition of Star Capital 26, Inc., execute significant capital raises through equity sales and warrant exercises, and convert preferred stock, all of which are expected to impact the company's capital structure and strategic direction.

Management Comments

• Menachem Shalom, the CEO and a director of the Company, is also the CEO, a director, and the controlling shareholder of Star Capital 26, Inc.

Industry Context

This filing reflects a common strategy among growth-oriented companies to expand through acquisition and secure capital for operations and strategic initiatives. The reliance on equity financing and convertible instruments suggests a focus on leveraging shareholder support for future growth, which is typical in sectors requiring substantial investment.

Corporate Governance

Related Party Transactions

• The Star Purchase Proposal involves a related party transaction where Menachem Shalom, the CEO and a director of Nukkleus Inc., is also the CEO, a director, and the controlling shareholder of Star Capital 26, Inc., the company being acquired.

Stakeholder Impact

• Shareholders: Will experience significant dilution due to the various share issuances, but also benefit from the company's strengthened capital position and strategic growth initiatives. The overwhelming approval suggests shareholders are aligned with these strategic moves despite dilution.
• Employees: Potential for integration challenges and opportunities related to the acquisition of Star Capital 26, Inc.
• Creditors: The capital raises could improve the company's financial stability, potentially reducing credit risk.

Next Steps

• Proceed with the acquisition of 100% of Star Capital 26, Inc.
• Issue shares upon the exercise of restricted common stock purchase warrants.
• Execute the Common Stock Purchase Agreement with Esousa Group Holdings, LLC to sell up to $250,000,000 of Common Stock.
• Facilitate the conversion of Series A Convertible Preferred Stock and exercise of associated warrants.
• File a registration statement for the conversion shares, which will trigger automatic conversion of Series A Preferred Stock.

Key Dates

Recommendation

The overwhelming shareholder approval for strategic acquisitions and significant capital raises provides a clear path for growth and financial stability. However, the substantial dilution from multiple equity issuances and the related-party nature of the Star acquisition introduce elements of risk and potential downward pressure on per-share value. While the company is executing on its strategy, investors should monitor the integration of Star Capital and the impact of dilution on future earnings per share before considering a stronger position.

Keywords

Nukkleus Inc., NUKK, SEC filing, 8-K, stockholder meeting, corporate governance, capital raise, acquisition, Star Capital 26, Esousa Group Holdings, Series A Preferred Stock, warrants, share issuance, dilution, Nasdaq Listing Rule 5635, related party transaction